BR0005122A - Método para a preparação de inibidor de permutador de sódio-hidrogênio do tipo 1 - Google Patents

Método para a preparação de inibidor de permutador de sódio-hidrogênio do tipo 1

Info

Publication number
BR0005122A
BR0005122A BR0005122-5A BR0005122A BR0005122A BR 0005122 A BR0005122 A BR 0005122A BR 0005122 A BR0005122 A BR 0005122A BR 0005122 A BR0005122 A BR 0005122A
Authority
BR
Brazil
Prior art keywords
sodium
preparation
type
hydrogen exchanger
exchanger inhibitor
Prior art date
Application number
BR0005122-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Norma Jacqueline Tom
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0005122A publication Critical patent/BR0005122A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/10Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by doubly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0005122-5A 1999-10-29 2000-10-30 Método para a preparação de inibidor de permutador de sódio-hidrogênio do tipo 1 BR0005122A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16237799P 1999-10-29 1999-10-29

Publications (1)

Publication Number Publication Date
BR0005122A true BR0005122A (pt) 2001-06-19

Family

ID=22585372

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0005122-5A BR0005122A (pt) 1999-10-29 2000-10-30 Método para a preparação de inibidor de permutador de sódio-hidrogênio do tipo 1

Country Status (19)

Country Link
US (1) US6441176B1 (cg-RX-API-DMAC7.html)
EP (1) EP1101763A3 (cg-RX-API-DMAC7.html)
JP (1) JP3342475B2 (cg-RX-API-DMAC7.html)
KR (2) KR100449595B1 (cg-RX-API-DMAC7.html)
CN (1) CN1146557C (cg-RX-API-DMAC7.html)
AR (1) AR029188A1 (cg-RX-API-DMAC7.html)
AU (1) AU779106B2 (cg-RX-API-DMAC7.html)
BR (1) BR0005122A (cg-RX-API-DMAC7.html)
CA (1) CA2324640A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20004018A3 (cg-RX-API-DMAC7.html)
HU (1) HUP0004187A2 (cg-RX-API-DMAC7.html)
ID (1) ID27904A (cg-RX-API-DMAC7.html)
IL (1) IL139198A0 (cg-RX-API-DMAC7.html)
PL (1) PL343542A1 (cg-RX-API-DMAC7.html)
RU (1) RU2190605C2 (cg-RX-API-DMAC7.html)
TR (1) TR200003143A2 (cg-RX-API-DMAC7.html)
TW (1) TWI221152B (cg-RX-API-DMAC7.html)
YU (1) YU62900A (cg-RX-API-DMAC7.html)
ZA (1) ZA200006007B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852733B2 (en) 2000-04-28 2005-02-08 Pfizer Inc. Sodium-hydrogen exchanger type 1 inhibitor
WO2002060892A1 (en) * 2001-01-31 2002-08-08 Pfizer Products Inc. Ethanolates of sodium-hydrogen exchanger type-1 inhibitor
CA2469305A1 (en) * 2001-12-19 2003-06-26 Frank Robert Busch Methods for preparing sodium-hydrogen exchanger type-1 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4028381A (en) * 1975-05-05 1977-06-07 Ciba-Geigy Corporation Pyrazolobenzazepines
DE4226649A1 (de) * 1992-08-12 1994-02-17 Bayer Ag Neue isobutylsubstituierte Methansulfonyl-chinolylmethoxyphenyl-cycloalkylessigsäureaminole
RU2009129C1 (ru) * 1991-12-16 1994-03-15 Центр по химии лекарственных средств Арилгидразоны 5,6,7,8-тетрагидрохинолиндионы-2,5, обладающие кардиотонической активностью
US6184380B1 (en) * 1999-01-25 2001-02-06 Pfizer Inc. Process for preparing naphthyridones and intermediates
US6492401B1 (en) 1998-02-27 2002-12-10 Pfizer, Inc. N-[(substituted five-membered di- or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia
UA72002C2 (en) 1999-10-29 2005-01-17 Pfizer Prod Inc Inhibitors crystals of sodium-hydrogen exchange of 1 type, a method for the preparation thereof (variants), a pharmaceuticalcomposition based thereon and a method for the reduction of tissue damage

Also Published As

Publication number Publication date
JP3342475B2 (ja) 2002-11-11
KR20010060211A (ko) 2001-07-06
KR100443851B1 (ko) 2004-08-11
ZA200006007B (en) 2002-04-26
US6441176B1 (en) 2002-08-27
CZ20004018A3 (cs) 2002-04-17
HUP0004187A2 (hu) 2002-11-28
EP1101763A3 (en) 2002-04-24
TR200003143A2 (tr) 2001-05-21
HU0004187D0 (cg-RX-API-DMAC7.html) 2001-01-29
EP1101763A2 (en) 2001-05-23
YU62900A (sh) 2003-08-29
AU6133300A (en) 2001-05-03
ID27904A (id) 2001-05-03
HK1036057A1 (en) 2003-07-10
RU2190605C2 (ru) 2002-10-10
KR100449595B1 (ko) 2004-09-21
CN1146557C (zh) 2004-04-21
AU779106B2 (en) 2005-01-06
KR20030061767A (ko) 2003-07-22
CA2324640A1 (en) 2001-04-29
IL139198A0 (en) 2001-11-25
PL343542A1 (en) 2001-05-07
CN1295070A (zh) 2001-05-16
TWI221152B (en) 2004-09-21
AR029188A1 (es) 2003-06-18
JP2001158784A (ja) 2001-06-12

Similar Documents

Publication Publication Date Title
DK1076657T3 (da) Hidtil ukendte hydroxyindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling
NO20032994D0 (no) VLA-4 inhibitorer
PT1162969E (pt) Utilizacao de inibidores da dipeptidilpeptidase iv para a melhoria da fertilidade
TR200002480T2 (tr) İzaşemi tedavisi için guanidin türevleri
BR0112786A (pt) Inibidores de inflamação não-esteroidais
NO20013463D0 (no) <omega>-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
NO20021407D0 (no) Bifenylderivater anvendt som NHE-3-inhibitorer
DZ3186A1 (fr) Ptéridinones utilisées comme inhibiteurs de kinase.
NO996491D0 (no) 4-brom- eller 4-iod-fenylaminobenzhydroksamsyre-derivater og deres anvendelse som MEK-inhibitorer
NO20016319L (no) VLA-4 inhibitor-forbindelser
NO20003018D0 (no) Triazinangiogenese-inhibitorer
DK1097127T3 (da) Diacylhydrazinderivater som integrininhibitorer
BR0007589A (pt) Inibidores da proliferação de células
DK0950657T3 (da) Substituerede carbazoler, fremgangsmåde til deres fremstilling og deres anvendelse som sPLA2-inhibitorer
BR0212925A (pt) Derivados de idol como inibidores de cox ii
NO20023001D0 (no) Substituerte piperazinderivater som MTP inhibitorer
BR0005122A (pt) Método para a preparação de inibidor de permutador de sódio-hidrogênio do tipo 1
BR0112028A (pt) Inibidores de farnesil transferase
YU79602A (en) Sodium-hydrogen exchanger type 1 inhibitor (nhe-1)
BR0015275A (pt) Cristais de inibidores de permutadores sódio-hidrogênio do tipo 1
NO20021965D0 (no) Hydroksamsyrederivat som inhibitor av dannelsen av opplöselig, human CD23
BR0107204A (pt) Inibidores da angiogênese de hidrazida e alcoxiamida
BR0110205A (pt) Inibidores de peptìdeo deformilase
ES1045580Y (es) Gasa para intervenciones quirurgicas.
BR9807920A (pt) Processos para tratamento de uma demência em um sujeito e para prevenção de uma demência

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.